New model developed
HUB Organoids™ to evaluate epithelial barrier function
Compromised intestinal barrier function has been associated with a number of intestinal and systemic diseases, including inflammatory bowel disease (IBD), obesity, metabolic disorders, and graft versus host disease. Limited approved agents that target the intestinal epithelial barrier integrity are presently available for IBD due also to the lack of predictive and physiologically relevant preclinical models. Our new published paper discusses the development of a new HUB organoids-based model to assess drug efficacy and safety, as well as absorption, metabolism, transport and permeability.
Read this paper to:
- Learn about the establishment of intestinal organoid-derived epithelial monolayers
- Discover how they can be applied to measuring epithelial barrier integrity, permeability, transport, as well as antimicrobial protein secretion
- Find out how to study the effects and mode of action of your compound on target cells by enriching organoid monolayers with key differentiated epithelial cells